Merdad Parsey, Chief Medical Officer of Gilead Sciences Inc (GILD, Financial), sold 2,000 shares of the company on October 1, 2024. The transaction was reported in a recent SEC Filing. Following this transaction, the insider now owns 100,189 shares of the company.
Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Over the past year, Merdad Parsey has sold a total of 37,476 shares of Gilead Sciences Inc and has not purchased any shares. The insider transaction history for the company shows a total of 11 insider sells and no insider buys over the past year.
On the date of the latest sale, shares of Gilead Sciences Inc were trading at $83.83, giving the company a market cap of approximately $105.50 billion. The price-earnings ratio of the stock stands at 103.34, significantly higher than the industry median of 24.38.
According to the GF Value, the intrinsic value of Gilead Sciences Inc is estimated at $75.10 per share, making the stock modestly overvalued with a price-to-GF-Value ratio of 1.12.
The valuation metrics, including the price-to-free cash flow, price-sales ratio, and price-book ratio, are calculated based on historical trading multiples, adjustments for past performance, and future business performance estimates provided by Morningstar analysts.
This sale by the insider may be of interest to current and potential investors, providing insight into insider confidence and stock valuation perceptions at Gilead Sciences Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
